ClinicalTrials.gg
TerminatedNCT06664853OLE_NEATUpdated May 5, 2026Results posted

Open-Label Extension of EryDex Study IEDAT-04-2022

A Phase 3 interventional study of Dexamethasone sodium phosphate in Ataxia Telangiectasia, sponsored by Quince Therapeutics S.p.A.. Terminated at 21 sites in 9 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Quince Therapeutics S.p.A. · Phase 3, Interventional, and Treatment

Why this study was terminated
eDSP development discontinued

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Ataxia Telangiectasia with a site in United States — 2 open to participants now, 4 under way, 1 of them phase 3. Ataxia Telangiectasia · United States.

Enrollment
3rd of 13
101 · median 20
Started
2024
with 1 other
Phase 3
4 of 16
none open now
Registered
14th of 16
by date
Lead sponsor
4 of 16
Quince Therapeutics S.p.A.

Among the 16 studies in Ataxia Telangiectasia with a site in United States, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 3, and was the 14th registered.

Ataxia Telangiectasia

42 studies on the registry are indexed under Ataxia Telangiectasia; 7 are open to participants now.

Browse Ataxia Telangiectasia studies →

Open to participants now

2 of the 16 studies in Ataxia Telangiectasia with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Ataxia Telangiectasia studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Ataxia Telangiectasia with a site in United States, or all of them as a file.
02

Study summary

This is an international, multi-center, prospective, open-label, non-comparative study aiming to provide access to treatment with EryDex to ataxia telangiectasia (A-T) patients who completed the IEDAT-04-2022 trial which studied the neurological effects of EryDex on subjects with ataxia telangiectasia (NEAT trial).

Read the detailed description

The IEDAT-05-2024 study aims to provide EryDex (dexamethasone sodium phosphate encapsulated into autologous erythrocytes) treatment to all participants in the IEDAT-04-2022 (NEAT) study, who complete the study assessments, do not -have safety contraindications to continuation of treatment, and who provide informed consent. The open-label extension (OLE) treatment period will be 12 months. Participants will be considered to have completed the study when Visit 14 (Safety Follow-up) has been performed.

03

Conditions studied

  • Ataxia Telangiectasia

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • body weight ≥15 kg
  • participation in IEDAT-04-2022 study and its completion, including final efficacy and safety assessments

Exclusion criteria

Exclusion Criteria:

  • safety for continuation of treatment, as determined by the investigator
  • immune impairment that, in the opinion of the Investigator, precludes further treatment with
  • Current neoplastic disease or previous neoplastic disease not in remission for at least 2 years.
  • requiring treatment with a systemic corticosteroid
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Dexamethasone sodium phosphate

    intravenous (IV) infusion of dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes using the EryDex System (EDS)

    Drug: Dexamethasone sodium phosphate

Interventions

  • Dexamethasone Sodium Phosphate encapsulated in autologous erythrocytes and administered via intravenous (IV) infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events

    Number of participants presenting at least one treatment emergent adverse event (TEAE)

    Time frame: through study completion, up to approximately 13 months

  2. Number of Participants With Treatment Emergent Adverse Events Leading to Intervention Discontinuation

    Number of participants presenting at least one treatment emergent adverse event (TEAE) leading to intervention discontinuation

    Time frame: through study completion, up to approximately 13 months

  3. Number of Participants With Serious Adverse Events

    Number of participants presenting at least one serious adverse event (SAE)

    Time frame: through study completion, up to approximately 13 months

07

Results

Posted May 5, 2026

Participant flow

102 participants completed the full treatment period in the IEDAT-04-2022 study (NEAT), 101 NEAT study participants subsequently consented and enrolled in the open-label extension study IEDAT-05-2024 study (NEAT-OLE).

Participant flow — Overall Study
MilestoneDexamethasone Sodium Phosphate
Started101
Completed0
Not completed101
Withdrew: Study terminated by sponsor. no completers101

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events

Number of participants presenting at least one treatment emergent adverse event (TEAE)

Time frame:
through study completion, up to approximately 13 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsDexamethasone Sodium Phosphate
Number of Participants With Treatment Emergent Adverse Events71
PrimaryNumber of Participants With Treatment Emergent Adverse Events Leading to Intervention Discontinuation

Number of participants presenting at least one treatment emergent adverse event (TEAE) leading to intervention discontinuation

Time frame:
through study completion, up to approximately 13 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events Leading to Intervention Discontinuation
ParticipantsDexamethasone Sodium Phosphate
Number of Participants With Treatment Emergent Adverse Events Leading to Intervention Discontinuation1
PrimaryNumber of Participants With Serious Adverse Events

Number of participants presenting at least one serious adverse event (SAE)

Time frame:
through study completion, up to approximately 13 months
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events
ParticipantsDexamethasone Sodium Phosphate
Number of Participants With Serious Adverse Events5

Adverse events

Collected over From first dose through study completion approximately 13 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dexamethasone Sodium Phosphate0/101 (0%)5/101 (5%)71/101 (70.3%)
Most frequent serious events
Most frequent serious events
EventDexamethasone Sodium Phosphate
ConstipationGastrointestinal disorders1/101
TachycardiaCardiac disorders1/101
Gastrostomy tube site complicationInjury, poisoning and procedural complications1/101
Influenza AInfections and infestations1/101
BronchospasmRespiratory, thoracic and mediastinal disorders1/101
Lymphadenopathy in nasopharynxGeneral disorders1/101
Most frequent other events
Showing 10 of 13
Most frequent other events
EventDexamethasone Sodium Phosphate
PruritusSkin and subcutaneous tissue disorders18/101
VomitingGastrointestinal disorders12/101
NasopharyngitisInfections and infestations11/101
Upper respiratory tract infectionInfections and infestations9/101
Viral infectionInfections and infestations7/101
PyrexiaGeneral disorders7/101
DiarrhoeaGastrointestinal disorders6/101
GastroenteritisGastrointestinal disorders6/101
InfluenzaInfections and infestations6/101
CoughRespiratory, thoracic and mediastinal disorders6/101

Baseline characteristics

The total set (N=101) included all patients who provided informed consent or assent as documented by a date of informed consent or date of assent.

Age, Categorical
Age, Categorical(Participants)Dexamethasone Sodium Phosphate
<=18 years101
Between 18 and 65 years0
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Dexamethasone Sodium Phosphate
Female48
Male53
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dexamethasone Sodium Phosphate
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American5
White86
More than one race0
Unknown or Not Reported4
08

Study locations

21 sites
  • University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence
    Los Angeles, California 90095, United States
  • The Johns Hopkins Hospital, Division of pediatric allergy and immunology
    Baltimore, Maryland 21289, United States
  • Saint Peter's University Hospital, Inc.
    New Brunswick, New Jersey 08901, United States
  • Cincinnati Children's Hospital, Division of neurology
    Cincinnati, Ohio 45229, United States
  • UT Health Houston, Department of pediatrics, division of child &amp;amp; adolescent neurology
    Houston, Texas 77030, United States
  • Copenhagen University Hospital, Rigshospitalet, Department of Pediatric Neurology
    Copenhagen, Denmark 2100, Denmark
  • University Hospital Frankfurt, Pediatric and Adolescent Clinic
    Frankfurt, Germany 60590, Germany
  • IKF Pneumologie GmbH & Co. KG; Institut für klinische Forschung Pneumologie Clinical Research Center Respiratory Diseases
    Frankfurt am Main, Hesse 60596, Germany
  • Spedali Civili di Brescia, Pediatric immunology department
    Brescia, Italy 25213, Italy
  • Policlinico Umberto I, La sapienza University, Department of neurosciences and menthal health
    Roma, Italy 00161, Italy
  • Oslo University Hospital, Rikshospitalet, Division of Pediatric and Adolescent Medicine, Norwegian National Unit for Newborn Screening
    Oslo, Norway 0372, Norway
  • MedPolonia sp zoo
    Poznan, 60-693, Poland
  • Instytut "Pomnik-Centrum Zdrowia Dziecka", Immunology clinic
    Warsaw, 04-736, Poland
  • Hospital Universitari Vall d'Hebron, Department of pediatric neurology
    Barcelona, Spain 08035, Spain
  • Hospital Universitario La Paz, Department of pediatric neurology
    Madrid, Spain 28046, Spain
  • Universitary Hospital Virgen del Rocío
    Seville, 41013, Spain
  • University Children's Hospital Zürich - Eleonore Foundation
    Zurich, CH 8008, Switzerland
  • Great Ormond Street Hospital for Children, Zayed Centre for Research
    London, United Kingdom WC1N 1DZ, United Kingdom
  • Nottingham Children's Hospital, Queen's Medical Center, Children's neurology
    Nottingham, United Kingdom NG7 2UH, United Kingdom
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, B152GW, United Kingdom
  • St George's University Hospitals NHS Foundation Trust, Centre for Neonatal and Paediatric Infection
    London, SE1 7EH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Jan 2026, 13 months.

Results were first posted in May 2026, 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2024
First posted
Oct 30, 2024
StartActual
Dec 11, 2024
Primary completionActual
Jan 30, 2026
CompletionActual
Jan 30, 2026
Results first posted
May 5, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06664853
Lead sponsor
Quince Therapeutics S.p.A.
Collaborators
Biotrial
Responsible party
Sponsor
First posted
Oct 30, 2024
Start date
Dec 11, 2024
Primary completion
Jan 30, 2026
Completion
Jan 30, 2026
Results posted
May 5, 2026
Last update
May 5, 2026

Study contacts

Dirk Thye, MD
study director · Quince Therapeutics S.p.A.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone phosphate

Start the discussion